spacer
home > ebr > summer 2019 > mass spectrometric analysis of process-related impurities
PUBLICATIONS
European Biopharmaceutical Review

Mass Spectrometric Analysis of Process-Related Impurities

The production process of any biological drug requires the use of a wide range of chemicals, such as nutrient media, initiators of protein production, selection processes (eg, antibiotics), and chemicals used in the subsequent purification processes. Furthermore, any chemical modifications to the naturally produced biologic, such as PEGylation, will result in an even larger number of chemicals coming into contact with the drug product. All of these extraneous chemicals can end up in small amounts in the final product (despite the significant purification strategies applied during downstream processing) and may be capable of generating a biological response such as an immune reaction or other adverse event in a patient, therefore putting them at risk. Moreover, the product itself may be at risk from extended exposure to these chemicals, such as increased levels of oxidation or aggregation or other chemical modification. Changes to the structure of the product as a result of the action of these residual levels of chemicals can lead to decreased shelf life, increase in aggregation, or other adverse effects, ultimately resulting in a loss of efficacy.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Richard L Easton obtained his PhD in glycoprotein structural characterisation using mass spectrometry from Imperial College of Science, Technology, and Medicine, UK. He subsequently spent several years there as a postdoctoral Research Scientist, working in the field of glycoprotein structural characterisation with emphasis on glycan elucidation. Richard moved to GlaxoSmithKline for a short time where he was Head of Mass Spectrometry for the toxicoproteomics and safety assessment group. He joined M-Scan (now part of SGS Life Sciences) as a Biochemist and became the Team Leader for carbohydrate analysis before being appointed Principal Scientist. Richard joined BioPharmaSpec in 2016 as Technical Director for Structural Analysis and is responsible for management of all aspects of carbohydrate and glycoprotein characterisation at the primary structure level.

Dr Andrew J Reason is the founder, CEO, and Managing Director at BioPharmaSpec. He has 25 years of experience in analysis of both novel and biosimilar biopharmaceuticals and has been involved in the commercialisation of a number of analytical methods for characterising proteins. In addition to his scientific and managerial duties, Andrew has contributed to many industry publications and is a regular presenter at conferences. He is also currently a Visiting Professor at the University of Warwick, UK.
spacer
Dr Richard L Easton
spacer
spacer
spacer
Dr Andrew J Reason
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Distributor Oppurtunities

Have an appetite for success Want to expand your product portfolio Fancy being part of something special??
More info >>

White Papers

EU GDP Guidelines: Implications for Shipping Clinical Materials into the European Market

PCI Pharma Services

Recently, the UKs Medicines and Healthcare products Regulatory Agency (MHRA) opened an investigation into a patient complaint of mold on paracetamol (acetaminophen) tablets (1). It discovered the product was shipped by sea from India to multiple companies in the UK at temperatures reaching up to 60 degrees Celsius. Labeling for paracetamol tablets typically states they should be kept below 30 degrees Celsius. In addition, MHRA discovered the humidity levels exceeded 80 percent during shipping, which is too high for the packaging that was used.
More info >>

 
Industry Events

CPhI Korea

21-23 August 2019, COEX, Seoul, South Korea

CPhI Korea provides a dynamic meeting place for a wide range of industry suppliers to engage with purchasers and decision makers from the pharmaceutical industry in Korea and the surrounding region. The exhibition showcases the whole pharma supply chain from ingredients, contracting services to machinery and biopharmaceuticals. It also hosts an extensive conference programme covering the latest trends and topics within the regional market.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement